冲高回落后探底回升，出现了止跌企稳的继续，截止午盘，恒生指数小涨0.21%。银行涨幅居前，恒生 医疗、大消费紧随其后，恒生科技逆势绿盘。 恒生科技高开低走，盘中一度下跌2.63%，截止午盘下跌0.97%。其中快手大跌4.35%，百度集团下跌 3.54%，腾讯控股下跌3.09%，比亚迪股份、阿里巴巴、美团、小米集团等股跌幅均在1%上方。 内容只是个人观点，仅供参考，不作为投资依据！欢迎关注交流，互相学习、共同探讨！ 恒生医疗高开低走后探底回升，截止午盘上涨0.72%。其中石药集团大涨4.15%，药明生物上涨3.12%， 百济神州上涨2.78%；三生制药、康方生物、京东健康等股逆势回撤。 恒生银行跳空高开后维持在高位窄幅盘整，截止午盘上涨1.2%。其中渣打银行上涨3.84%，汇丰控股上 涨2.45%，中银香港上涨2.33%，大新银行、重庆银行、大新金融等股涨幅均在1%上方。 ...

当生物制药工艺赛道的国产化替代浪潮风起云涌，背靠药明生物这棵"大树"的多宁生物，却在资本市场的门外三度徘徊。 近日，这家国内首家商业化无血清培养基的生物工艺解决方案提供商，第三次向港交所递交招股书，试图以2025年前三季度扭亏为盈的业绩拐点，叩开上 市大门。 然而，这份看似回暖的成绩单背后，是无法回避的三重隐忧。 药明生物作为第二大股东、第一大客户兼供应商的双重绑定，让关联交易公允性质疑如影随形；8.43亿元商誉高悬，或存并购标的业绩不及预期的减值风 险；3.89亿元的短期借款，让仅有3.02亿元的类现金储备的多宁生物，资金链压力倍增。 三重枷锁之下，多宁生物的第三次IPO征程，终究要在机遇与风险的博弈中艰难前行。 狂奔二十年，陷"增收不增利"泥潭？ 早在2005年，多宁生物就已在中国扎根起步，彼时，公司仅是一家从事细胞培养基研发的小型技术企业。 由于动物细胞广泛应用于科研及生物药物开发生产，细胞培养基是维持动物细胞体外生长的核心必备原料，应用覆盖药物早期开发、基础科研及疫苗、抗 体等生物药物生产。 2016年，公司董事长兼首席执行官、执行董事王猛以18万元收购60%股权入主公司，此后通过持续引入外部融资、推 ...

Core Insights - Hubei Jichuan Pharmaceutical Co., Ltd. has secured exclusive commercialization rights for two innovative drugs, Inusimab injection and Pumexitin (PG-011) nasal spray, enhancing its product portfolio [1][2][3] Group 1: Commercialization Agreements - Jichuan Pharmaceutical signed an exclusive commercialization agreement for Inusimab injection, a PCSK9 monoclonal antibody for treating primary hypercholesterolemia and mixed dyslipidemia, with a payment of 80 million yuan (including tax) and potential milestone payments of up to 10 million yuan [2] - The Inusimab injection is expected to be approved for market launch in September 2024 and included in the National Medical Insurance Drug List in 2025 [2] - Jichuan Pharmaceutical also signed an exclusive commercialization agreement for Pumexitin nasal spray, a JAK1/2 inhibitor for allergic rhinitis, with a payment of up to 100 million yuan (including tax) [3] Group 2: Financial Performance and Challenges - Jichuan Pharmaceutical's core products have faced declining sales, leading to a decrease in revenue and net profit. In 2024, the company reported an operating revenue of 8.017 billion yuan, down 16.96%, and a net profit of 2.532 billion yuan, down 10.32% [8] - The sales of key products, including Pudilan anti-inflammatory oral liquid and pediatric Qiqiao Qingre granules, have been negatively impacted by market demand changes and pricing policies, resulting in significant revenue declines [8][9] - In the first three quarters of 2025, the company continued to experience a downward trend, with operating revenue of 3.932 billion yuan, down 32.27%, and a net profit of 1.022 billion yuan, down 46.27% [9]

Core Viewpoint - The Hang Seng Index Company announced that the technology and biotechnology sectors will perform prominently in the Hong Kong stock market in 2025, with both the Hang Seng Technology Index and the Hang Seng Biotechnology Index achieving their best annual performance since their inception. In this context, the Hang Seng Dual Technology Index will be launched in January 2026, combining the constituents of both indices into a single index to highlight these two key themes [1][3]. Group 1: Performance of Indices - The Hang Seng Technology Index recorded a 23.5% increase in 2025, marking its highest annual growth since its launch in July 2020 [3]. - The Hang Seng Biotechnology Index achieved a remarkable 64.5% increase in 2025, representing its best annual performance since its inception in December 2019 [3]. - The strong performance of these indices is driven by structural factors and improvements in fundamentals [3]. Group 2: Industry Trends - The technology sector in China is a focal point, receiving clear and long-term policy support, with "significantly improving the level of technological self-reliance" being a major goal in China's 14th Five-Year Plan (2026-2030) [6]. - Artificial intelligence (AI) has become a key area of market focus, with Chinese AI models gaining global recognition [6]. - The Hang Seng Technology Index represents 30 of the largest technology companies listed in Hong Kong, focusing on areas such as smart technology, cloud computing, digital commerce, and fintech [6]. Group 3: Biotechnology Sector - The Chinese biotechnology sector has gained significant attention due to the increasing global recognition of innovative drugs developed in China, with the total value of outbound licensing transactions for innovative drugs reaching a record high of $136 billion in 2025 [7]. - This record transaction volume indicates a significant enhancement in the global competitiveness and technical capabilities of the Chinese biotechnology industry [7]. - The Hang Seng Biotechnology Index, which tracks the performance of the largest 30 biotechnology companies listed in Hong Kong, recorded a historic 64% annual increase in 2025 and continued to rise by 9% in January 2026 [8]. Group 4: Launch of the Hang Seng Dual Technology Index - The Hang Seng Dual Technology Index, launched on January 9, 2026, combines the two themes of technology and biotechnology, with a weight allocation of 75% to the Hang Seng Technology Index and 25% to the Hang Seng Biotechnology Index [12]. - The index recorded a 36% increase in 2025, with a continued upward trend into 2026, reflecting ongoing market interest in Chinese innovation themes [12]. - As of January 30, 2026, the index had a one-year annualized volatility of 34%, lower than the 35% and 40% of the Hang Seng Technology Index and Hang Seng Biotechnology Index, respectively, indicating a balanced risk profile [12].

Market Overview - The US stock market experienced a decline, with the Chinese concept index dropping by 0.94%. The Hang Seng Index fell by 110.27 points, a decrease of 0.41%, closing at 26,724.50 points, while the Hang Seng Tech Index dropped by 120.19 points, down 2.20%, reaching a new low since mid-July 2025 [1] - Technology stocks, particularly those considered riskier, continued to decline, with Tencent falling nearly 4% after restrictions on its "Yuanbao Red Packet" link by WeChat. Other major players like Baidu, Meituan, and Xiaomi also saw declines of over 2%, while Bilibili dropped nearly 5% [1] - Chip stocks faced significant losses, with Shanghai Fudan down nearly 9%, Huahong Semiconductor down over 5%, and SMIC down nearly 3% [1] - The coal sector showed strength, with Feishang No Smoke Coal rising over 33%. Real estate stocks also performed well, with Sunac China up over 7% and China Resources Land up nearly 4% [1] Corporate Developments - In the technology sector, InnoCare successfully completed a significant design integration for AI hardware with Google, establishing a solid foundation in the AI hardware market [1] - Enoch Intelligent received a milestone payment of HKD 39 million from Menarini, marking a significant step in its pharmaceutical technology research [1] - Capital investment firm Shumeng Capital signed a contract worth USD 3 million with a Macau distributor, expanding its business footprint [1] Pharmaceutical Industry Highlights - Youzhiyou Biotech's M701 received FDA IND approval for a novel therapy targeting malignant pleural effusion, marking a new phase in international clinical development [2] - Xiansheng Pharmaceutical received a milestone payment of USD 40 million from AbbVie for the overseas licensing option agreement for SIM0500, highlighting its competitiveness in the international pharmaceutical market [2] - Kangfang Biotech granted exclusive commercialization rights for Yixinning® to Jichuan Pharmaceutical, resulting in significant licensing fees and milestone payments [2] - Federal Pharmaceuticals' UBT251 injection received implied clinical trial approval for a new indication, providing new treatment options for patients [2] Food Industry Performance - Nissin Foods reported strong performance in its China business segment, with revenue reaching JPY 54.948 billion, a year-on-year increase of 2.7%, and core operating profit of JPY 5.859 billion, up 9.3% [2] Capital Market Insights - Guotai Junan International noted a market shift from "liquidity-driven" to "profit-driven" dynamics, suggesting a focus on fundamental analysis rather than speculative trading [4] - CITIC Securities observed significant adjustments in Hong Kong stock earnings expectations, predicting a continuation of the spring market rally with large-cap stocks outperforming [4] - Huatai Securities indicated that the current market sentiment has shifted to optimism, suggesting a focus on companies with earnings certainty and potential for growth in technology and cyclical sectors [5] - Guoyuan International highlighted that Hong Kong stocks may continue to outperform US stocks due to favorable conditions for non-US assets and the potential recovery of domestic demand [5]

Major Events - InnoCare Pharma (09926) granted exclusive commercialization rights of Yixineng® to Jichuan Pharmaceutical [1] - Ying Si Intelligent (03696) received a milestone payment of HKD 39 million from Menarini, with the MEN2501 project completing its first patient dosing [1] - Xiansheng Pharmaceutical (02096) received a recent milestone payment related to the overseas licensing option agreement for SIM0500 with AbbVie [1] - Innovent Biologics (02577) completed significant design integration for related products on Google's AI hardware platform and signed a compliant supply agreement [1] - Federal Pharmaceutical (03933) obtained implied approval for clinical trials of UBT251 injection for OSA indications [1] - Kanghong Pharmaceutical (00867) received clinical trial approval for the innovative drug CMS-D017 capsule for complement-mediated kidney disease indications [1] - First Capital Holdings (00697) announced the successful IPO and listing of Shimon Holdings on the Shenzhen Stock Exchange [1] Operating Performance - Country Garden (02007) achieved a contract sales amount of approximately CNY 2.21 billion attributable to shareholders by January 2026 [1] - Nissin Foods (01475) reported an operating profit of JPY 5.672 billion from its China business segment for the first three quarters, representing a year-on-year increase of 99.8% [1] - Natural Beauty (00157) issued a profit warning, expecting an annual net profit of approximately HKD 8 million to HKD 10 million, marking a turnaround from losses [1]

Core Viewpoint - Kangfang Biopharma has signed an exclusive commercialization rights agreement with Jichuan Pharmaceutical, granting Jichuan the exclusive rights to commercialize the drug Yixinning (Inusimab Injection) in mainland China, excluding Hong Kong, Macau, and Taiwan [1][2]. Group 1: Agreement Details - Kangfang Biopharma will receive a total of RMB 80 million (including tax) as an upfront licensing fee from Jichuan Pharmaceutical, along with potential milestone payments not exceeding RMB 10 million (including tax) [1]. - Jichuan Pharmaceutical will be responsible for the commercialization, promotion, and sales of Yixinning in the authorized market [1]. Group 2: Product Information - Yixinning (Inusimab Injection) is a novel PCSK9 monoclonal antibody developed by Kangfang Biopharma, approved for market in September 2024 for treating primary hypercholesterolemia and mixed dyslipidemia, including heterozygous familial hypercholesterolemia (HeFH) [2]. - The drug has been included in the latest National Medical Insurance Directory and is highly recommended in the 2025 edition of expert consensus on managing cardiovascular risks related to blood lipids [2]. - Yixinning works by specifically binding to PCSK9, blocking its interaction with LDL-R, thereby restoring LDL-R expression levels to enhance the clearance of LDL-C from plasma [2].

Group 1 - Jichuan Pharmaceutical has announced the acquisition of exclusive commercialization rights for Kangfang Biotech's PCSK9 monoclonal antibody in mainland China, following a previous announcement regarding a JAK1/JAK2 inhibitor [2] - The company will pay a total of 80 million yuan (including tax) as an authorization fee and up to 10 million yuan (including tax) in milestone payments [4] - The PCSK9 monoclonal antibody, named Inusimab, is designed to specifically bind to PCSK9 and block its interaction with low-density lipoprotein receptors (LDL-R), thereby enhancing the clearance of low-density lipoprotein cholesterol (LDL-C) from the plasma [4] Group 2 - Inusimab is expected to be approved for market launch in September 2024, primarily for the treatment of primary hypercholesterolemia and mixed dyslipidemia, including heterozygous familial hypercholesterolemia (HeFH) and hypercholesterolemia in patients with atherosclerotic cardiovascular disease [4] - The drug will be included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List for 2025, officially implemented from January 1, 2026 [4]

伊喜宁®通过特异性结合PCSK9并阻断其与LDL-R的相互作用，恢复LDL-R的表达水平以提升对血浆中 LDL-C的清除能力。既往研究表明，在他汀类药物背景治疗的基础上接受PCSK9单抗治疗可显著减少人 体的胆固醇水平，降低患者心脏病发作和中风的风险。III期临床研究显示，伊喜宁®对于超高危、极高 危、高危及中低危分层的患者，以及无论LDL-C情况的患者，均具有优异临床疗效，为高胆固醇血症的 临床治疗、心血管风险的长期控制提供了新的选择。 康方生物(09926)公布，公司间接全资附属公司中山康方生物医药有限公司、康融东方(广东)医药有限公 司(以下合称"康方生物")与湖北济川药业股份有限公司全资子公司济川药业集团有限公司、江苏济源医 药有限公司(以下合称"济川药业")于近日签署《独佔性商业化权益协议》，康方生物授权济川药业在合 作期限内，在中华人民共和国(不含中国香港、中国澳门特别行政区和中国台湾地区)拥有公司自主开发 并已获批上市的伊喜宁®(伊努西单抗注射液)的独家商业化权益。本次合作，康方生物将获得由济川药 业支付的人民币8,000万元(含税)授权费，以及最高不超过人民币1,000万元(含税)的里程碑付款 ...

格隆汇2月3日丨康方生物(09926.HK)宣布，公司间接全资附属公司中山康方生物医药有限公司、康融东 方(广东)医药有限公司(以下合称「康方生物」)与湖北济川药业股份有限公司全资子公司济川药业集团 有限公司、江苏济源医药有限公司(以下合称「济川药业」)于近日签署《独占性商业化权益协议》，康 方生物授权济川药业在合作期限内，在中华人民共和国(不含香港、澳门特别行政区和台湾地区)拥有公 司自主开发并已获批上市的伊喜宁?(伊努西单抗注射液)的独家商业化权益。本次合作，康方生物将获 得由济川药业支付的人民币8,000万元(含税)授权费，以及最高不超过人民币1,000万元(含税)的里程碑付 款；济川药业将负责伊喜宁?在授权市场的商业化推广和销售。 ...